Pharmaceutical gallium compositions and methods
Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.
1. A complex comprising a metal ion and a compound represented by structural formula I:
2-OH—Ar—CR 1 —NR 2 —R 3 —COOH I
wherein 2-OH—Ar is an optionally substituted 2-hydroxyaryl;
R 1 is —OH or ═O;
R 2 is hydrogen, hydroxyl or an optionally substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or C 2 -C 4 alkenyl; and
R 3 is an optionally substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, C 1 -C 24 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynl, C 1 -C 10 alkylaryl, C 1 -C 10 arylalkyl, C 2 -C 10 alkenylaryl, C 2 -C 10 arylalkenyl, C 2 -C 10 alkynylaryl or C 2 -C 10 arylalkynyl, which optionally is interrupted by O, N, S or any combination thereof.
2. The complex of claim 1 , wherein the metal ion is selected from the group consisting of Ca, Sr, Mg, Cr, Zn, Au, Ag, Fe, Ni, Cu, Pt, Co, Ti, Tc, Sr, Ln, Gd, Pb, Al, Cd, Ra, and Po.
3. The complex of claim 2 , wherein the compound is represented by the formula:
wherein Z is H or a halo and n is 3-11.
4. The complex of claim 1 , wherein the complex exhibits increased oral bioavailability upon administration compared to uncomplexed metal ion.
5. A method for preparing a complex comprising reacting a metal ion with a compound represented by structural formula I:
2-OH—Ar—CR 1 —NR 2 —R 3 —COOH I
wherein 2-OH—Ar is an optionally substituted 2-hydroxyaryl;
R 1 is —OH or ═O;
R 2 is hydrogen, hydroxyl or an optionally substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or C 2 -C 4 alkenyl; and
R 3 is an optionally substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, C 1 -C 24 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynl, C 1 -C 10 alkylaryl, C 1 -C 10 arylalkyl, C 2 -C 10 alkenylaryl, C 2 -C 10 arylalkenyl, C 2 -C 10 alkynylaryl or C 2 -C 10 arylalkynyl, which optionally is interrupted by O, N, S or any combination thereof,
under conditions sufficient to form said complex.
6. The method of claim 5 , wherein the metal ion is selected from the group consisting of Ca, Sr, Mg, Cr, Zn, Au, Ag, Fe, Ni, Cu, Pt, Co, Ti, Tc, Sr, Ln, Gd, Pb, Al, Cd, Ra, and Po.
7. The method of claim 6 , wherein the compound is represented by the formula:
wherein Z is H or a halo and n is 3-11.
8. A composition comprising a metal ion, a compound represented by structural formula I:
2-OH—Ar—CR 1 —NR 2 —R 3 —COOH I
wherein 2-OH—Ar is an optionally substituted 2-hydroxyaryl;
R 1 is —OH or ═O;
R 2 is hydrogen, hydroxyl or an optionally substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or C 2 -C 4 alkenyl; and
R 3 is an optionally substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, C 1 -C 24 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynl, C 1 -C 10 alkylaryl, C 1 -C 10 arylalkyl, C 2 -C 10 alkenylaryl, C 2 -C 10 arylalkenyl, C 2 -C 10 alkynylaryl or C 2 -C 10 arylalkynyl, which optionally is interrupted by O, N, S or any combination thereof,
and at least one pharmaceutically acceptable excipient.
9. The composition of claim 8 , wherein the metal ion is selected from the group consisting of Ca, Sr, Mg, Cr, Zn, Au, Ag, Fe, Ni, Cu, Pt, Co, Ti, Tc, Sr, Ln, Gd, Pb, Al, Cd, Ra, and Po.
10. The composition of claim 9 , wherein the composition is in solid form for oral administration.
11. The composition of claim 10 , wherein the composition further comprises a means to inhibit dissociation of the complex under the acidic conditions of the stomach.
12. The composition of claim 9 , wherein the composition is a nutritional composition.
13. The composition of claim 12 , wherein the metal ion is selected from the group consisting of Ca, Sr, Mg, Cr, Zn, Au, Ag, Fe, Ni, and Cu.
14. The composition of claim 9 , wherein the composition is a therapeutic composition.
15. The composition of claim 14 , wherein the metal ion is selected from the group consisting of Au, Ag, Pt, Zn, Ca, Fe, Mg, Sr, and Co.
16. The composition of claim 9 , wherein the composition is a diagnostic composition.
17. The composition of claim 16 , wherein the metal ion is selected from the group consisting of Ti, Tc, Sr, Ln, and Gd.
18. The composition of claim 8 , wherein the metal ion is a radioisotope.
19. A method for removing an unwanted metal ion from body tissue or blood comprising treating the body tissue or blood with a compound represented by structural formula I:
2-OH—Ar—CR 1 —NR 2 —R 3 —COOH I
wherein 2-OH—Ar is an optionally substituted 2-hydroxyaryl;
R 1 is —OH or ═O;
R 2 is hydrogen, hydroxyl or an optionally substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or C 2 -C 4 alkenyl; and
R 3 is an optionally substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, C 1 -C 24 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynl, C 1 -C 10 alkylaryl, C 1 -C 10 arylalkyl, C 2 -C 10 alkenylaryl, C 2 -C 10 arylalkenyl, C 2 -C 10 alkynylaryl or C 2 -C 10 arylalkynyl, which optionally is interrupted by O, N, S or any combination thereof, whereby the unwanted metal ion is removed from the body tissue or blood.
20. The method of claim 19 , wherein the unwanted metal ion is selected from the group consisting of Pb, Al, Cd, Ag, Cu, Sr, Ra, and Po.